세계의 CRISPR 유전자 편집 치료 시장 예측(-2032년) : 제품별, 용도별, 최종 사용자별, 지역별 분석

According to Stratistics MRC, the Global CRISPR Gene Editing Therapies Market is accounted for $5.3 billion in 2025 and is expected to reach $14.4 billion by 2032 growing at a CAGR of 15.2% during the forecast period. CRISPR gene editing therapies are advanced medical interventions that utilize the CRISPR-Cas9 technology to precisely modify an organism's DNA. By targeting specific genes, these therapies can correct genetic mutations, disable harmful genes, or introduce beneficial genetic sequences, offering potential cures for inherited disorders, cancers, and viral infections. Unlike traditional treatments, CRISPR therapies aim to address the root cause of diseases at the genetic level. Ongoing research focuses on improving precision, safety, and delivery methods, making CRISPR a transformative approach in personalized and regenerative medicine.

Market Dynamics:

Driver:

Rapid technological advances in CRISPR platforms

Precision editing tools such as base editors and prime editors are improving targeting accuracy and reducing off-target effects. Integration with AI-driven design and high-throughput screening is enhancing candidate selection and validation. Developers are launching modular delivery systems and multiplexed editing protocols for complex indications. Investment in platform scalability and automation is improving reproducibility and regulatory readiness. These innovations are propelling clinical translation and pipeline expansion across global biotech ecosystems.

Restraint:

Delivery challenges for in vivo targets

Viral vectors and lipid nanoparticles face barriers in tissue specificity, immunogenicity, and payload capacity. Crossing the blood-brain barrier and achieving systemic distribution remain difficult for neurological and metabolic disorders. Developers must balance editing efficiency with toxicity and immune response management. Regulatory scrutiny around delivery platforms is increasing across clinical trials. These limitations continue to constrain progress in systemic and multi-organ therapies.

Opportunity:

Growing prevalence of genetic and rare diseases

Monogenic disorders such as sickle cell anemia, Duchenne muscular dystrophy, and cystic fibrosis are driving early clinical adoption. Rare disease foundations and patient advocacy groups are funding translational research and trial recruitment. Regulatory agencies are offering expedited pathways for orphan indications and breakthrough therapies. Integration with newborn screening and genomic diagnostics is improving early intervention potential. These dynamics are fostering long-term demand for precision gene editing solutions.

Threat:

High manufacturing and therapy costs

GMP-grade production of reagents, vectors, and cell therapies requires specialized infrastructure and skilled labor. Batch variability and quality control complexity increase operational burden and regulatory risk. Pricing models for one-time curative therapies remain uncertain across payers and health systems. Reimbursement frameworks are evolving slowly, especially for rare and ultra-rare conditions. These cost pressures continue to hamper commercial viability and equitable access.

Covid-19 Impact:

The pandemic accelerated investment in CRISPR technologies for diagnostics, vaccine development, and therapeutic innovation. CRISPR-based detection platforms were deployed for rapid COVID-19 screening and variant tracking. Supply chain disruptions affected reagent availability and delayed trial timelines across gene editing programs. Remote collaboration and digital lab tools gained traction in academic and biotech settings. Public awareness of genomic medicine increased as CRISPR entered mainstream discourse. These shifts are accelerating long-term integration of CRISPR into global health strategies.

The CRISPR kits & reagents segment is expected to be the largest during the forecast period

The CRISPR kits & reagents segment is expected to account for the largest market share during the forecast period due to their foundational role in research, diagnostics, and therapeutic development. These products include nucleases, guide RNAs, delivery systems, and validation tools used across academic, clinical, and commercial labs. Demand is rising for high-fidelity enzymes, customizable libraries, and scalable reagent formats. Vendors are offering modular kits tailored to cell type, organism, and editing workflow. Integration with automation platforms and cloud-based design tools is improving throughput and reproducibility.

The academic & research institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the academic & research institutes segment is predicted to witness the highest growth rate as universities and public labs expand CRISPR programs across basic science and translational medicine. Institutions are launching genome engineering centers, collaborative consortia, and open-access toolkits to accelerate innovation. Funding from government agencies and philanthropic organizations is supporting early-stage research and proof-of-concept studies. Academic labs are driving breakthroughs in delivery, specificity, and multiplexing that feed into commercial pipelines. Partnerships with biotech firms and CROs are enabling clinical trial readiness and IP licensing.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced biotech infrastructure, regulatory engagement, and academic excellence. The United States hosts the largest concentration of CRISPR startups, research institutions, and clinical trial sponsors. NIH and DARPA funding is supporting platform innovation and therapeutic validation across rare and complex diseases. FDA guidance on gene editing therapies is improving clarity and accelerating approvals. Canada is scaling translational research and public-private partnerships across genomics and regenerative medicine. These factors are boosting North America's leadership in CRISPR-based therapeutic development.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as genomic medicine, academic investment, and translational infrastructure converge. Countries like China, Japan, South Korea, and India are expanding CRISPR research across agriculture, diagnostics, and human therapeutics. Government-backed programs are funding genome editing centers, biomanufacturing hubs, and clinical trial networks. Local firms are launching region-specific therapies tailored to population genetics and disease burden. Academic institutions are publishing high-impact research and collaborating with global biotech leaders.

Key players in the market

Some of the key players in CRISPR Gene Editing Therapies Market include CRISPR Therapeutics AG, Editas Medicine, Inc., Intellia Therapeutics, Inc., Beam Therapeutics Inc., Caribou Biosciences, Inc., Mammoth Biosciences, Inc., Scribe Therapeutics, Inc., Graphite Bio, Inc., Tessera Therapeutics, Inc., eGenesis, Inc., Verve Therapeutics, Inc., Sherlock Biosciences, Inc., Metagenomi, Inc., ToolGen, Inc. and Cellectis S.A.

Key Developments:

In September 2025, Editas Medicine officially selected EDIT-401 as its lead in vivo development candidate, signaling a strategic pivot toward cardiometabolic applications. The company emphasized its focus on durable, single-dose therapies using optimized CRISPR/Cas9 delivery platforms.

In May 2025, CRISPR Therapeutics entered a multi-target strategic collaboration with Sirius Therapeutics to co-develop and co-commercialize long-acting siRNA programs (notably SRSD107), committing upfront cash and equity investments and agreeing to a cost/profit sharing and regional commercialization split.

Products Covered:

• CRISPR Kits & Reagents
• CRISPR Plasmids & Vectors
• Design & Customization Tools
• Gene Editing Platforms & Software
• Contract Research & Manufacturing Services (CRO/CMO)
• Gene Synthesis & Sequencing Services
• Gene Expression Analysis Tools
• Other Products

Applications Covered:

• Therapeutic Development
• Drug Discovery & Screening
• Functional Genomics
• Stem Cell & Regenerative Medicine
• Precision Medicine / Personalized Therapy
• Immunotherapy Development
• Gene Therapy Clinical Trials
• Pharmacogenomics
• Target Validation
• Other Applications

End Users Covered:

• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Hospitals & Specialty Clinics
• Government & Regulatory Bodies
• Diagnostics Companies
• Biomanufacturing Firms
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global CRISPR Gene Editing Therapies Market, By Product

• 5.1 Introduction
• 5.2 CRISPR Kits & Reagents
• 5.3 CRISPR Plasmids & Vectors
• 5.4 Design & Customization Tools
• 5.5 Gene Editing Platforms & Software
• 5.6 Contract Research & Manufacturing Services (CRO/CMO)
• 5.7 Gene Synthesis & Sequencing Services
• 5.8 Gene Expression Analysis Tools
• 5.9 Other Products

6 Global CRISPR Gene Editing Therapies Market, By Application

• 6.1 Introduction
• 6.2 Therapeutic Development
  • 6.2.1 Rare Genetic Disorders
  • 6.2.2 Oncology
  • 6.2.3 Hematologic Diseases
  • 6.2.4 Infectious Diseases
• 6.3 Drug Discovery & Screening
• 6.4 Functional Genomics
• 6.5 Stem Cell & Regenerative Medicine
• 6.6 Precision Medicine / Personalized Therapy
• 6.7 Immunotherapy Development
• 6.8 Gene Therapy Clinical Trials
• 6.9 Pharmacogenomics
• 6.10 Target Validation
• 6.11 Other Applications

7 Global CRISPR Gene Editing Therapies Market, By End User

• 7.1 Introduction
• 7.2 Pharmaceutical & Biotech Companies
• 7.3 Academic & Research Institutes
• 7.4 Hospitals & Specialty Clinics
• 7.5 Government & Regulatory Bodies
• 7.6 Diagnostics Companies
• 7.7 Biomanufacturing Firms
• 7.8 Other End Users

8 Global CRISPR Gene Editing Therapies Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 CRISPR Therapeutics AG
• 10.2 Editas Medicine, Inc.
• 10.3 Intellia Therapeutics, Inc.
• 10.4 Beam Therapeutics Inc.
• 10.5 Caribou Biosciences, Inc.
• 10.6 Mammoth Biosciences, Inc.
• 10.7 Scribe Therapeutics, Inc.
• 10.8 Graphite Bio, Inc.
• 10.9 Tessera Therapeutics, Inc.
• 10.10 eGenesis, Inc.
• 10.11 Verve Therapeutics, Inc.
• 10.12 Sherlock Biosciences, Inc.
• 10.13 Metagenomi, Inc.
• 10.14 ToolGen, Inc.
• 10.15 Cellectis S.A.